NLRP3 and Parkinson disease: Moreover, oral administration of the NLRP3 inhibitor (MCC950) in Parkinson's disease models inhibited inflammasome activation, leading to improvements in motor function, protection against nigrostriatal dopaminergic neuron loss and reduced accumulation of α-syn aggregates.150 Another report also suggests that microglial inflammation may enhance prion-like spread of α-syn in the brain.151 Intracerebral injection of a variant of α-syn less capable of fibril formation in mice revealed a greater inflammatory response than WT α-syn.